Market Research Report
Global Osteoarthritis Drugs Market - 2019-2026
|Published by||DataM Intelligence||Product code||834579|
|Published||Content info||130-180 Pages
Delivery time: 1-2 business days
|Global Osteoarthritis Drugs Market - 2019-2026|
|Published: May 1, 2019||Content info: 130-180 Pages||
The Global Osteoarthritis Drugs market is expected to be USD XX million in 2017 and grow at a CAGR of XX% to reach a market value of USD XX million by 2026.
Osteoarthritis (OA) is the most common form of arthritis, affecting millions of people worldwide. It is a degenerative disease that worsens over time and occurs when the protective cartilage on the person's bones wears down. The disorder generally affects joints in the knees, hips, hands, and spine. Osteoarthritis drugs cannot reverse the disorder but are instead used to manage symptoms such as pain, inflammation, etc. effectively.
The global market for the Osteoarthritis Drugs Market is primarily driven by the rising geriatric population and increasing incidence of orthopedic disorders. According to the United Nations (UN), an estimated 10% - 15% of all adults aged over 60 have some degree of OA, with the prevalence higher in women than men. UN estimated that by 2050 people aged over 60 will account for more than 20% of the world's population, of which 15-20% (around 130 million people) are estimated to have symptomatic OA, and one-third of these people will be severely disabled (about 40 million people). Other factors such as the increasing awareness concerning degenerative bone diseases, the rise of obesity in the population, increasing incidents of occupational injury and trauma to the joints, expanding R&D activities and a robust pipeline portfolio of drugs with lesser side effects are expected to boost the global osteoarthritis drugs market. According to the World Health Organization (WHO), 2016, more than 1.9 billion adults aged 18 years and older were overweight, of these over 650 million adults were obese.
However, the high cost of drug development and the severe side-effects associated with the drugs may hinder the market progress.
By Route of Administration, the global Osteoarthritis Drugs market includes Oral, Parenteral, and Topical. The topical segment holds a significant share of the market and is expected to grow at a steady pace as it is a preferred route of administration for patients with risks of sensitive stomach or heart problems, mainly seen in people older than 65.
By Drug Class, the global Osteoarthritis Drugs market is segmented into NSAIDs, Analgesics, Corticosteroids, Hyaluronic Acid, and Others. Non-steroidal Anti-inflammatory Drugs (NSAIDs) holds a substantial market share and is expected to grow during the forecast period. It is due to NSAIDs being the most common drug used to ease pain, stiffness, and inflammation that comes with arthritis. Moreover, NSAIDs are cheap and is considered the first choice in pain management of Osteoarthritis. The hyaluronic acid segment is expected to be the fastest growing market share due to its effective and rapid pain relieving property. Hyaluronic Acid is used as a treatment option when a patient is no longer able to handle osteoarthritis pain with NSAIDs. The Hyaluronic Acid segment accounted for a higher share of the market, in terms of value than NSAIDs and corticosteroids segments as they are more costly. It is likely to expand at a rapid pace during the forecast period.
North America dominates the global osteoarthritis drugs market owing to the high prevalence of Osteoarthritis, growing obese population and high acceptance of Hyaluronic Acid-based drugs. According to the Arthritis Foundation, 2017, a conservative estimate indicating that about 54 million adults and almost 300,000 children were officially diagnosed with arthritis in the US and a recent study estimates that as many as 91 million Americans have arthritis. One in three people age 18-64 has arthritis. According to the Centers for Disease Control and Prevention, by 2040, an estimated 78.4 million (25.9% of the projected total adult population) adults aged 18 years and older will have doctor-diagnosed arthritis. Moreover, the high awareness among the people, government reimbursement policies, and the presence of significant players in the region are expected to supplement the growth of the regional osteoarthritis drugs market.
The Asia-Pacific market is expected to grow at the fastest rate during the forecast period due to availability of large base of the patient pool. Also, increasing elderly population and rising disposable income are boosting the growth of the market. The main factor positively influencing the market in this region is improving healthcare access and infrastructure in countries such as China and India. Furthermore, Japan is the second-largest market for hyaluronic acid products after the US, which in turn is anticipated to boost the market in the Asia Pacific further.
Key players are adopting strategies such as mergers and acquisitions, partnerships, and regional expansion to stand out as strong competitors in the market. New product launches and strong pipeline drugs are other ways the leading players improve their market presence.
In May 2019, AKL Research & Development and Nordic Bioscience Clinical Development, announce a collaboration (risk-share agreement) to assess the efficacy of a novel, oral medicine, APPA, in a phase II trial of osteoarthritis.
In February 2019, UK biotech AKL Research and Development received a grant from a UK government-backed innovation body to develop its osteoarthritis drug. The treatment is only at the phase 1 trial stage, but Innovate the UK has awarded the Stevenage-based firm £675,000 to help it get to phase 2 development underway.
In January 2019, Pfizer and Eli Lilly and Company announced that their Tanezumab hit two out of three co-primary endpoints in one dose and all three with a higher dose in patients with moderate-to-severe osteoarthritis pain in a Phase III trial. Tanezumab is a humanized monoclonal antibody that inhibits NGF. It is believed that by inhibiting NGF, the drug may prevent pain signals created by muscles, skin, and organs from reaching the spinal cord and brain.
In November 2018, Galapagos NV announced that the FDA had granted GLPG1972/S201086 a Fast Track designation for the treatment of patients with Osteoarthritis. Galapagos is developing investigational molecule GLPG1972/S201086 with the potential to become a first-in-class disease-modifying osteoarthritis drug (DMOAD) as part of a collaboration with Servier, an international pharmaceutical company, signed in 2010.